Schwab Andrew J.
CIK 0001598549 Name as filed on the most recent filing
Filed as Schwab Andrew J. (67)
177 transaction lines · from 67 filings · filed 2014-09-25 to 2026-08-20 The span is the filing dates this catalog holds, not the entity's full filing history. Absence here is not evidence of absence at the SEC.
A line appears here when the filing that carries it names this CIK as a reporting owner, not only when the parser picked this CIK as the line's primary owner. That is why a joint filing appears on both owners' pages rather than vanishing from the second one. The catalog never merges two CIKs into one person and never splits one CIK into two: identity here is the SEC's own identifier and nothing else.
Issuers this insider has filed against
Ordered by last-seen filing date, newest first. Roles are as filed on the Form 4 and are not normalised.
This container could not be filled from the store. It is showing nothing because a read failed, not because no insider filed: those are different facts and this catalog will not let one stand in for the other. The last ingest the store recorded was 2026-08-21 05:23 UTC.
- ISSUER Skye Bioscience, Inc. 3 filings
- ISSUER Entrada Therapeutics, Inc. 6 filings
- ISSUER Camp4 Therapeutics Corp 1 filings
- ISSUER Artiva Biotherapeutics, Inc. 1 filings
- ISSUER Enliven Therapeutics, Inc. 4 filings
- ISSUER Pear Therapeutics, Inc. 6 filings
- ISSUER Rallybio Corp 5 filings
- ISSUER scPharmaceuticals Inc. 5 filings
- ISSUER CinCor Pharma, Inc. 2 filings
- ISSUER Vor Biopharma Inc. 2 filings
- ISSUER Cabaletta Bio, Inc. 5 filings
- ISSUER Impel Neuropharma Inc 1 filings
- ISSUER Akouos, Inc. 2 filings
- ISSUER Homology Medicines, Inc. 6 filings
- ISSUER Ideaya Biosciences, Inc. 2 filings
- ISSUER Aprea Therapeutics, Inc. 5 filings
- ISSUER Arvinas, Inc. 3 filings
- ISSUER Crinetics Pharmaceuticals, Inc. 4 filings
- ISSUER Audentes Therapeutics, Inc. 1 filings
- ISSUER Viveve Medical, Inc. 2 filings
- ISSUER Epirus Biopharmaceuticals, Inc. 1 filings
No issuer is recorded
The catalog holds no filing linking this CIK to an issuer.
Transactions
Every stored Form 4 line naming this reporting owner, newest transaction date first. Each row links to the filing it came from.
21 transactions · Newest transaction date first, id breaking the tie.
This container could not be filled from the store. It is showing nothing because a read failed, not because no insider filed: those are different facts and this catalog will not let one stand in for the other. The last ingest the store recorded was 2026-08-21 05:23 UTC.
| Direction | Date | Issuer | Code | Shares | Price | Value USD | Filing |
|---|---|---|---|---|---|---|---|
| 2026-08-20 |
Skye Bioscience, Inc. SKYE |
S, Open-market sale | 6,495 disposed | 0.32 | 2,078.40 | Form 4, filing 0001598549-26-000005 | |
| 2026-08-20 |
Skye Bioscience, Inc. SKYE |
S, Open-market sale | 46 disposed | 0.32 | 14.72 | Form 4, filing 0001598549-26-000005 | |
| 2026-08-20 |
Skye Bioscience, Inc. SKYE |
S, Open-market sale | 1,159 disposed | 0.32 | 370.88 | Form 4, filing 0001598549-26-000005 | |
| 2026-08-19 |
Skye Bioscience, Inc. SKYE |
S, Open-market sale | 57,476 disposed | 0.35 | 20,116.60 | Form 4, filing 0001598549-26-000005 | |
| 2026-08-19 |
Skye Bioscience, Inc. SKYE |
S, Open-market sale | 409 disposed | 0.35 | 143.15 | Form 4, filing 0001598549-26-000005 | |
| 2026-08-19 |
Skye Bioscience, Inc. SKYE |
S, Open-market sale | 10,255 disposed | 0.35 | 3,589.25 | Form 4, filing 0001598549-26-000005 | |
| 2026-08-18 |
Skye Bioscience, Inc. SKYE |
S, Open-market sale | 253,080 disposed | 0.38 | 96,170.40 | Form 4, filing 0001598549-26-000005 | |
| 2026-08-18 |
Skye Bioscience, Inc. SKYE |
S, Open-market sale | 1,830 disposed | 0.38 | 695.40 | Form 4, filing 0001598549-26-000005 | |
| 2026-08-18 |
Skye Bioscience, Inc. SKYE |
S, Open-market sale | 45,090 disposed | 0.38 | 17,134.20 | Form 4, filing 0001598549-26-000005 | |
| 2026-08-07 |
Entrada Therapeutics, Inc. TRDA |
S, Open-market sale | 52,317 disposed | 6.85 | 358,371.45 | Form 4, filing 0001231919-26-000854 | |
| 2026-08-06 |
Entrada Therapeutics, Inc. TRDA |
S, Open-market sale | 10,494 disposed | 7.00 | 73,458.00 | Form 4, filing 0001231919-26-000854 | |
| 2026-07-31 |
Entrada Therapeutics, Inc. TRDA |
S, Open-market sale | 1,718 disposed | 6.85 | 11,768.30 | Form 4, filing 0001231919-26-000822 | |
| 2026-07-30 |
Entrada Therapeutics, Inc. TRDA |
S, Open-market sale | 114,756 disposed | 6.93 | 795,259.08 | Form 4, filing 0001231919-26-000822 | |
| 2025-11-14 |
Entrada Therapeutics, Inc. TRDA |
S, Open-market sale | 200,000 disposed | 8.80 | 1,760,000.00 | Form 4, filing 0001231919-25-000522 | |
| 2025-08-22 |
Skye Bioscience, Inc. SKYE |
S, Open-market sale | 163,979 disposed | 3.42 | 560,808.18 | Form 4, filing 0001415889-25-022808 | |
| 2025-08-22 |
Skye Bioscience, Inc. SKYE |
S, Open-market sale | 6,470 disposed | 3.42 | 22,127.40 | Form 4, filing 0001415889-25-022808 | |
| 2025-08-21 |
Skye Bioscience, Inc. SKYE |
S, Open-market sale | 58,642 disposed | 3.57 | 209,351.94 | Form 4, filing 0001415889-25-022808 | |
| 2025-08-21 |
Skye Bioscience, Inc. SKYE |
S, Open-market sale | 2,314 disposed | 3.57 | 8,260.98 | Form 4, filing 0001415889-25-022808 | |
| 2025-07-09 |
Entrada Therapeutics, Inc. TRDA |
S, Open-market sale | 20,065 disposed | 7.50 | 150,527.63 | Form 4, filing 0001415889-25-019677 | |
| 2025-07-09 |
Entrada Therapeutics, Inc. TRDA |
S, Open-market sale | 6,935 disposed | 7.50 | 52,026.37 | Form 4, filing 0001415889-25-019677 | |
| 2025-07-01 |
Entrada Therapeutics, Inc. TRDA |
S, Open-market sale | 18,578 disposed | 7.12 | 132,323.66 | Form 4, filing 0001415889-25-018822 | |
| 2025-07-01 |
Entrada Therapeutics, Inc. TRDA |
S, Open-market sale | 6,422 disposed | 7.12 | 45,741.34 | Form 4, filing 0001415889-25-018822 | |
| 2025-06-30 |
Entrada Therapeutics, Inc. TRDA |
S, Open-market sale | 18,578 disposed | 6.81 | 126,566.34 | Form 4, filing 0001415889-25-018822 | |
| 2025-06-30 |
Entrada Therapeutics, Inc. TRDA |
S, Open-market sale | 6,422 disposed | 6.81 | 43,751.16 | Form 4, filing 0001415889-25-018822 | |
| 2025-06-27 |
Entrada Therapeutics, Inc. TRDA |
S, Open-market sale | 55,735 disposed | 6.91 | 385,128.85 | Form 4, filing 0001415889-25-018822 | |
| 2025-06-27 |
Entrada Therapeutics, Inc. TRDA |
S, Open-market sale | 19,265 disposed | 6.91 | 133,121.15 | Form 4, filing 0001415889-25-018822 | |
| 2024-10-15 |
Camp4 Therapeutics Corp CAMP |
P, Open-market purchase | 909,090 acquired | 11.00 | 9,999,990.00 | Form 4, filing 0001104659-24-108702 | |
| 2024-09-13 |
Skye Bioscience, Inc. SKYE |
S, Open-market sale | 11,758 disposed | 6.06 | 71,253.48 | Form 4, filing 0001415889-24-023401 | |
| 2024-09-13 |
Skye Bioscience, Inc. SKYE |
S, Open-market sale | 2,000 disposed | 6.06 | 12,120.00 | Form 4, filing 0001415889-24-023401 | |
| 2024-09-13 |
Skye Bioscience, Inc. SKYE |
S, Open-market sale | 79 disposed | 6.06 | 478.74 | Form 4, filing 0001415889-24-023401 | |
| 2024-09-11 |
Skye Bioscience, Inc. SKYE |
S, Open-market sale | 214,556 disposed | 6.60 | 1,416,069.60 | Form 4, filing 0001415889-24-023401 | |
| 2024-09-11 |
Skye Bioscience, Inc. SKYE |
S, Open-market sale | 36,504 disposed | 6.60 | 240,926.40 | Form 4, filing 0001415889-24-023401 | |
| 2024-09-11 |
Skye Bioscience, Inc. SKYE |
S, Open-market sale | 1,440 disposed | 6.60 | 9,504.00 | Form 4, filing 0001415889-24-023401 | |
| 2024-07-22 |
Artiva Biotherapeutics, Inc. ARTV |
P, Open-market purchase | 833,333 acquired | 12.00 | 9,999,996.00 | Form 4, filing 0001415889-24-020035 | |
| 2024-02-14 |
Enliven Therapeutics, Inc. ELVN |
S, Open-market sale | 688,358 disposed | 14.90 | 10,256,534.20 | Form 4, filing 0001415889-24-004111 | |
| 2024-02-14 |
Enliven Therapeutics, Inc. ELVN |
S, Open-market sale | 136,642 disposed | 14.90 | 2,035,965.80 | Form 4, filing 0001415889-24-004111 | |
| 2024-01-31 |
Enliven Therapeutics, Inc. ELVN |
S, Open-market sale | 417,187 disposed | 15.00 | 6,257,805.00 | Form 4, filing 0001415889-24-002295 | |
| 2024-01-31 |
Enliven Therapeutics, Inc. ELVN |
S, Open-market sale | 82,813 disposed | 15.00 | 1,242,195.00 | Form 4, filing 0001415889-24-002295 | |
| 2023-09-26 |
Enliven Therapeutics, Inc. ELVN |
S, Open-market sale | 164,789 disposed | 15.00 | 2,471,835.00 | Form 4, filing 0001209191-23-050731 | |
| 2023-09-26 |
Enliven Therapeutics, Inc. ELVN |
S, Open-market sale | 32,711 disposed | 15.00 | 490,665.00 | Form 4, filing 0001209191-23-050731 | |
| 2023-08-24 |
Enliven Therapeutics, Inc. ELVN |
S, Open-market sale | 367,124 disposed | 16.00 | 5,873,984.00 | Form 4, filing 0001209191-23-047514 | |
| 2023-08-24 |
Enliven Therapeutics, Inc. ELVN |
S, Open-market sale | 72,876 disposed | 16.00 | 1,166,016.00 | Form 4, filing 0001209191-23-047514 | |
| 2023-04-10 |
Pear Therapeutics, Inc. PEAR |
S, Open-market sale | 12,836,489 disposed | 0.12 | 1,540,378.68 | Form 4, filing 0001209191-23-024105 | |
| 2023-04-10 |
Pear Therapeutics, Inc. PEAR |
S, Open-market sale | 3,172,769 disposed | 0.12 | 380,732.28 | Form 4, filing 0001209191-23-024105 | |
| 2023-04-10 |
Pear Therapeutics, Inc. PEAR |
S, Open-market sale | 534,855 disposed | 0.12 | 64,182.60 | Form 4, filing 0001209191-23-024105 | |
| 2023-03-07 |
Rallybio Corp RLYB |
S, Open-market sale | 100,000 disposed | 8.20 | 820,000.00 | Form 4, filing 0001209191-23-017533 | |
| 2022-11-15 |
Pear Therapeutics, Inc. PEAR |
S, Open-market sale | 61,222 disposed | 2.52 | 154,279.44 | Form 4, filing 0001209191-22-057195 | |
| 2022-11-15 |
Pear Therapeutics, Inc. PEAR |
S, Open-market sale | 2,551 disposed | 2.52 | 6,428.52 | Form 4, filing 0001209191-22-057195 | |
| 2022-11-14 |
Pear Therapeutics, Inc. PEAR |
S, Open-market sale | 11,643 disposed | 2.79 | 32,483.97 | Form 4, filing 0001209191-22-057195 | |
| 2022-11-14 |
Pear Therapeutics, Inc. PEAR |
S, Open-market sale | 485 disposed | 2.79 | 1,353.15 | Form 4, filing 0001209191-22-057195 |
This column is intentionally blank
No transaction line is stored for this reporting owner, though the catalog holds filings naming them. That happens when the filings report only holdings or only positions the store does not carry, and when a parse failed; each filing page states its own parse status.
- S, Open-market sale
- Open-market sale
- P, Open-market purchase
- Open-market purchase
Every value is as reported on the Form 4. A price the filing did not report is marked Not reported and no value is computed from it. Codes outside the open market, drawn in grey behind a dashed rule, are compensation and administrative machinery rather than a decision to trade at the prevailing price.
What this insider's stored lines contain
Exact counts over every stored line for this entity. This is a statement of composition, not a filter: the only filter this page offers is the open-market one above, because that is the only one an index serves today.
- Open-market purchase 2
- Open-market sale 19
- Option exercise 0
- Grant or award 0
- Tax withholding 0
- Disposition to the issuer 0
- In-the-money option exercise 0
How to cite this page
ebomi catalog. Schwab Andrew J., insider transactions. Retrieved 2026-08-21 from https://ebomi.com/insider/0001598549
Balogh, A. Insider trading. Scientific Data 10, 237 (2023) doi:10.1038/s41597-023-02147-6